Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners.
We are advancing a diverse pipeline of first-in-class or potentially best-in-class agents for hard-to-treat solid tumors and hematologic malignancies. This includes the industry’s leading SMARCA-targeted pipeline.
Our differentiation strategy is to design and optimize each of our small molecule therapeutics to possess specific properties that have the potential to benefit patients:
- PRT3789 (SMARCA2), we sought high selectivity over SMARCA4 to elicit synthetic lethality using a targeted protein degrader approach
- For PRT2527 (CDK9), we optimized for superior selectivity over previously developed CDK9i to improve tolerability
| Program | Potential Indications | Discovery | Phase 1 | Phase 2/3 | Upcoming Milestones |
|---|---|---|---|---|---|
| PR-01 | |||||
| Lead SMARCA2 Degrader (IV) |
SMARCA4-mutated NSCLC & other cancers | PRT3789 | Dose Confirmation by YE2024; Pembrolizumab Combo Trial Start in Q4 2024 | ||
| Oral SMARCA2 Degrader |
SMARCA4-mutated NSCLC & other cancers | PRT7732 | Phase I Trial Initiated | ||
| SMARCA2/4 Precision ADCs* |
Broad range of cancers (heme & solid tumors) | Expand SMARCA Portfolio to Address Cancers Without SMARCA4 Mutations | |||
| Next-Gen CDK9 Selective Inhibitor |
Myeloid and Lymphoid malignancies | PRT2527 | Interim Phase 1 Data Anticipated in Q4 2024 | ||
| Discovery Engine | Hard-to-treat cancers, “undruggable” targets, high unmet need | Deliver a First- or Best-in-Class New Program Every 12-18 Months | |||
| Precision ADCs* | Broad range of cancers (heme & solid tumors) | First Program to be Presented at Medical Conference in Q4 2024 | |||
| PR-01 | Lead SMARCA2 Degrader (IV) PRT3789 | |
| SMARCA4-mutated NSCLC & other cancers | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: Dose Confirmation by YE2024; Pembrolizumab Combo Trial Start in Q4 2024 | ||
| Oral SMARCA2 Degrader PRT7732 | ||
| SMARCA4-mutated NSCLC & other cancers | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: Phase I Trial Initiated | ||
| SMARCA2/4 Precision ADCs* | ||
| Broad range of cancers (heme & solid tumors) | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: Expand SMARCA Portfolio to Address Cancers Without SMARCA4 Mutations | ||
| Next-Gen CDK9 Selective Inhibitor PRT2527 | ||
| Myeloid and Lymphoid malignancies | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: Interim Phase 1 Data Anticipated in Q4 2024 | ||
| Discovery Engine | ||
| Hard-to-treat cancers, “undruggable” targets, high unmet need | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: Deliver a First- or Best-in-Class New Program Every 12-18 Months | ||
| Precision ADCs* | ||
| Broad range of cancers (heme & solid tumors) | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: First Program to be Presented at Medical Conference in Q4 2024 | ||
*In partnership with